Global Epidermal Growth Factor Receptor (EGFR) Antibodies Market Segment Forecasts up to 2021, Research Reports
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Published By: Syndicate <strong>Market</strong> <strong>Research</strong><br />
<strong>Epidermal</strong> <strong>Growth</strong> <strong>Fac<strong>to</strong>r</strong> <strong>Recep<strong>to</strong>r</strong> (<strong>EGFR</strong>) <strong>Antibodies</strong><br />
<strong>Market</strong> - <strong>Global</strong> Industry Perspective, Comprehensive<br />
Analysis and Forecast, 2015 – <strong>2021</strong><br />
Joel John<br />
3422 SW 15 Street, Suit #8138,<br />
Deerfield Beach,<br />
Florida 33442, USA<br />
Tel: +1-386-310-3803<br />
Toll Free: 1-855-465-4651<br />
sales@Syndicate<strong>Market</strong><strong>Research</strong>.com<br />
http://www.syndicatemarketresearch.com/
<strong>Epidermal</strong> <strong>Growth</strong> <strong>Fac<strong>to</strong>r</strong> <strong>Recep<strong>to</strong>r</strong> (<strong>EGFR</strong>) <strong>Antibodies</strong> <strong>Market</strong><br />
<strong>EGFR</strong> is the primary recep<strong>to</strong>r recognized in a gro<strong>up</strong> of recep<strong>to</strong>rs and is a cell surface protein that binds <strong>to</strong><br />
epidermal growth fac<strong>to</strong>r. <strong>EGFR</strong> is a cell membrane growth fac<strong>to</strong>r recep<strong>to</strong>r characterized by tyrosine kinase<br />
recep<strong>to</strong>r which plays very important role in the control of key cellular transduction pathways in both normal and<br />
cancerous cells. <strong>EGFR</strong> is the first molecular target against which monoclonal antibodies (mAb) have been<br />
developed in cancer therapy.<br />
On the basis of types, the global epidermal growth fac<strong>to</strong>r recep<strong>to</strong>r (<strong>EGFR</strong>) antibodies market is segmented<br />
in<strong>to</strong> cetuximab, panitumumab, and nimotuzumab. Cetuximab and panitumumab are the most favored <strong>EGFR</strong><br />
antibodies which are utilized for treatment of cancer. Nimotuzumab is a humanized monoclonal antibody that<br />
recognizes the <strong>EGFR</strong> antibody. These antibodies are used in the treatment of colorectal tumor as single<br />
chairmen and in mix with routine chemotherapy.<br />
Browse the full "<strong>Epidermal</strong> <strong>Growth</strong> <strong>Fac<strong>to</strong>r</strong> <strong>Recep<strong>to</strong>r</strong> (<strong>EGFR</strong>) <strong>Antibodies</strong> <strong>Market</strong> - <strong>Global</strong> Industry<br />
Perspective, Comprehensive Analysis and Forecast, 2015 – <strong>2021</strong>" report<br />
at http://www.syndicatemarketresearch.com/market-analysis/epidermal-growth-fac<strong>to</strong>r-recep<strong>to</strong>r-egfr-antibodiesmarket-global.html<br />
The report covers forecast and analysis for the epidermal growth fac<strong>to</strong>r recep<strong>to</strong>r (<strong>EGFR</strong>) antibodies market on<br />
a global and regional level. The study provides his<strong>to</strong>ric data of 2015 along with a forecast from 2016 <strong>to</strong> <strong>2021</strong><br />
based on revenue (USD Million). The report also offers detailed competitive landscape of the global epidermal<br />
sales@Syndicate<strong>Market</strong><strong>Research</strong>.com
<strong>Epidermal</strong> <strong>Growth</strong> <strong>Fac<strong>to</strong>r</strong> <strong>Recep<strong>to</strong>r</strong> (<strong>EGFR</strong>) <strong>Antibodies</strong> <strong>Market</strong><br />
growth fac<strong>to</strong>r recep<strong>to</strong>r (<strong>EGFR</strong>) antibodies market. It includes company market share analysis, product portfolio<br />
of the major industry participants. The report provides detailed segmentation of the epidermal growth fac<strong>to</strong>r<br />
recep<strong>to</strong>r (<strong>EGFR</strong>) antibodies market based on type segment. Cetuximab, panitumumab, and nimotuzumab are<br />
different type of <strong>EGFR</strong> antibodies.<br />
Increasing rate of cancer around the world, and advancement in the treatments are few drivers for <strong>EGFR</strong><br />
antibody market. Prevalence of cancer is high in North America specifically in U.S. Cancer cases globally are<br />
escalating at an alarming rate. Cancer represents a key challenge <strong>to</strong> development, undermining economic and<br />
social advances all over the world. Breast cancer is most common diagnosed cancer and second leading<br />
cause of death amongst women in the U.S. According <strong>to</strong> World Cancer Report, produced by the WHO's<br />
specialized cancer agency, predicted that new cancer cases would rise from 14 million annually in 2012 <strong>to</strong> 22<br />
million within two decades.<br />
Get Request Sample@ http://www.syndicatemarketresearch.com/request-forsample.html?flag=S&repid=67199<br />
Geographically, epidermal growth fac<strong>to</strong>r recep<strong>to</strong>r (<strong>EGFR</strong>) antibodies market has been segmented in<strong>to</strong> North<br />
America, Europe, Asia Pacific, Latin America, and Middle East & Africa. <strong>EGFR</strong> antibody market was<br />
dominated by North America followed by Europe. Key players in this market are Biocon ltd, Bris<strong>to</strong>l-Myers<br />
Squibb, Vaccinex, NovelMed Therapeutics, Janssen Biotech (J&J), Merck, Angiochem , Bio-Synthesis,<br />
Antibody Systems<br />
<strong>Epidermal</strong> <strong>Growth</strong> <strong>Fac<strong>to</strong>r</strong> <strong>Recep<strong>to</strong>r</strong> (<strong>EGFR</strong>) <strong>Antibodies</strong> <strong>Market</strong>: Type <strong>Segment</strong> Analysis<br />
sales@Syndicate<strong>Market</strong><strong>Research</strong>.com
<strong>Epidermal</strong> <strong>Growth</strong> <strong>Fac<strong>to</strong>r</strong> <strong>Recep<strong>to</strong>r</strong> (<strong>EGFR</strong>) <strong>Antibodies</strong> <strong>Market</strong><br />
<br />
<br />
<br />
Cetuximab<br />
Panitumumab<br />
Nimotuzumab<br />
<strong>Epidermal</strong> <strong>Growth</strong> <strong>Fac<strong>to</strong>r</strong> <strong>Recep<strong>to</strong>r</strong> (<strong>EGFR</strong>) <strong>Antibodies</strong> <strong>Market</strong>: Regional <strong>Segment</strong> Analysis<br />
<br />
North America<br />
o<br />
U.S.<br />
<br />
Europe<br />
o UK<br />
o France<br />
o Germany<br />
Get Request Sample@ http://www.syndicatemarketresearch.com/request-forsample.html?flag=S&repid=67199<br />
<br />
<br />
Asia Pacific<br />
o China<br />
o Japan<br />
o India<br />
Latin America<br />
sales@Syndicate<strong>Market</strong><strong>Research</strong>.com
<strong>Epidermal</strong> <strong>Growth</strong> <strong>Fac<strong>to</strong>r</strong> <strong>Recep<strong>to</strong>r</strong> (<strong>EGFR</strong>) <strong>Antibodies</strong> <strong>Market</strong><br />
<br />
o<br />
Brazil<br />
Middle East & Africa<br />
Browse the full "<strong>Epidermal</strong> <strong>Growth</strong> <strong>Fac<strong>to</strong>r</strong> <strong>Recep<strong>to</strong>r</strong> (<strong>EGFR</strong>) <strong>Antibodies</strong> <strong>Market</strong> - <strong>Global</strong> Industry<br />
Perspective, Comprehensive Analysis and Forecast, 2015 – <strong>2021</strong>" report<br />
at http://www.syndicatemarketresearch.com/market-analysis/epidermal-growth-fac<strong>to</strong>r-recep<strong>to</strong>r-egfr-antibodiesmarket-global.html<br />
Syndicate market research<br />
Address: Suite #8138, 3422 SW 15 Street, Deerfield Beach, Florida 33442, USA<br />
Tel: +1-386-310-3803<br />
FREE)<br />
Email: sales@Syndicate<strong>Market</strong><strong>Research</strong>.com<br />
Tel: +1-855-465-4651 (US/CAN TOLL<br />
Web:http://www.syndicatemarketresearch.com/<br />
sales@Syndicate<strong>Market</strong><strong>Research</strong>.com
Change language